Antifibrinolytics, Protamine, and DDVAP Flashcards
What is the purpose of antifibrinolytic medications?
prevents the lysis of fibrin
used to prevent and treat excessive bleeding as inhibitors of fibrinolysis
interfere with the formation by plasminogen activators (primarily t-PA and u-PA which takes place mainly in lysine rich areas on the surface of fibrin
Two types of competitive inhibition of plasminogen conversion to plasmin are
lysine analogs (txa and amicar) serine protease inhibitor (aprotinin)
Epsilon Aminocaproic Acid (amicar)
fda approved for use in the treatment of acute bleeding due to elevated fibrinolytic activity
inhibits the proteolytic enzyme plasmin, the enzyme responsible for fibrinolysis
Clinical uses of amicar
trauma, CPB, and spinal fusions
Dosing ranges of amicar
bolus: 5-15g (peds 75-150mg/kg)
infusion: 1-2 g/hr (peds 5-30mg/kg/hr)
Txa tranexamic Acid (cylokapron)
a synthetic analog of the amino acid lysine
inhibits fibrinolysis by competitvely binding to the lysine receptor sites on plasminogen
prevents plasmin from binding to and degrading fibrin which preserves the fibrin matrix structure
Parenteral TXA is
effective in treating bleeding from multiple causes such as GI , surgical and trauma
Half life of TXA is
2 hours
Which drug is more potent? AMinocaproic acid or TXA?
TXA by 8-10 times
Clinical uses of TXA
non-cerebral trauma peds- spinal fusions, craniosynostosis orthopedic procedures cardiac obsterics (massive transfusion)
Doses of TXA
10-15mg/kg IV (up to 1 gm) Following by an infusion of 1-5mg/kg/hr
$$$
CRASH-2 Trial
adults with traumatic bleeding showed that TXA reduces death due to bleeding wiht no increase in vascular occlusive events
patients treated within 3 hours of injury, TXA reduced death due to bleeding by 1/3 but after 3 hours increased risk of bleeding
TXA in Post Partum Hemorrhage
20,060 woman enrolled in study
death due to bleeding was significantly reduced in woman given TXA especially woman treated within 3 hours of giving birth (nearly 1/3) with no significant increase or decrease in any other cause of death
TXA contraindications
active intravascular clotting (pulmonary embolism, DVT, embolic cerebral stroke)
anaphlaxis
subarachnoid hemorrhage-associated with cerebral infarction
TXA precautions
eliminated unchanged in the urine- requires decreased dosing in patients with renal function impairment
UTI d/t clot formation
hypotension with rapid IV injection
color vision defect- visual changes in an indicator of toxicity
seizure disorders
concomitant administration with factor concentrates